Should interferon gamma release assays become the standard method for screening patients for Mycobacterium tuberculosis infections in the United States?

Journal of Clinical Microbiology

Volumn 49, Issue 6, 2011, Pages 2086-2092

  Alexander, Thomas S ^a   Miller, Melissa B ^b   Gilligan, Peter ^c  

^a SUMMA HEALTH SYSTEM   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON;

ANTIGEN SPECIFICITY; CELLULAR IMMUNITY; DELAYED HYPERSENSITIVITY; DIAGNOSTIC TEST ACCURACY STUDY; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; IMMUNOSTIMULATION; INFECTION CONTROL; INTERFERON GAMMA RELEASE ASSAY; INTERMETHOD COMPARISON; LYMPHOCYTE COUNT; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PERFORMANCE; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; TUBERCULIN TEST; TUBERCULOSIS;

CLINICAL LABORATORY TECHNIQUES; HUMANS; IMMUNOASSAY; INTERFERON-GAMMA; MASS SCREENING; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; UNITED STATES;

MYCOBACTERIUM TUBERCULOSIS;

EID: 79957504791     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00589-11     Document Type: Review

References (0)